Interface Biologics is working on medical implant coatings designed to fight infections, administer drugs and reduce the risk of blood clots. The Toronto-based company is in talks with potential partners in the device industry and expects its products to reach the market by 2010, said Tom Reeves, Interface's president and CEO.

Related Summaries